Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, switching costs, and cost-effectiveness

The peer-reviewed article evaluates the costs and cost-effectiveness of Ghana’s switch from ROTARIX to ROTAVAC for rotavirus vaccination in 2020. ROTAVAC, which has a lower price per dose and a smaller cold chain footprint but requires more doses per regimen, is compared to ROTARIX over ten years. The study uses primary data from six regions and estimates supply chain and service delivery costs, as well as the financial and economic costs of switching products. It finds that the supply chain and service delivery cost per dose is lower for ROTAVAC. The cost per disability-adjusted life-year (DALY) averted is also lower for ROTAVAC, making it more cost-effective. The switch from ROTARIX to ROTAVAC 5-dose was found to be cost-saving and switching to ROTAVAC 10-dose could offer further savings and should be considered.